The Simple Side Daily

The Simple Side Daily

Share this post

The Simple Side Daily
The Simple Side Daily
The Simple Side Morning Market Espresso

The Simple Side Morning Market Espresso

Thursday, July 17: A shot of actionable financial news that doesn't break the bank.

The Simple Side's avatar
The Simple Side
Jul 17, 2025
∙ Paid
1

Share this post

The Simple Side Daily
The Simple Side Daily
The Simple Side Morning Market Espresso
1
Share

In case you didn’t know, my main investing newsletter is located here:
NEWSLETTER LINK.

I had someone request the daily stock updates to include fundamental and technical analysis, so this will be added at the very end of the newsletter!

Enjoy and let me know what you would like to see added or changed about the newsletter by clicking here:

Start Survey


Help support this newsletter by subscribing for just $1 a month. Don’t waste your time dealing with biased articles from large corporations that only care about their ad revenue.

Join The Simple Side of things.

Support Me For $1

Market Overview

  • S&P 500: 6,301.50 (▼ 0.03%)

  • Dow: 44,381.00 (▼ 0.18%)

  • Nasdaq: 23,097.50 (▲ 0.09%)

Key Indicators

  • 10-Year Treasury: 4.48% (▼ 0.31%)

  • VIX: 17.16 (▼ 3.91%)

  • Gold: $3,322.20 (▼ 0.22%)

  • Oil: $67.01 (▼ 1.45%)

  • Bitcoin: $118,620.91 (▲ 0.48%)


Top News & Movers

Union Pacific (UNP)
Reportedly eyeing a major acquisition of either CSX (CSX) or Norfolk Southern (NSC), potentially forming a transcontinental railroad. CSX rose 5.4%, NSC gained 2.6%, while UNP slid 2.2% premarket.

Goldman Sachs (GS)
Hiked its dividend 33% to $4/share. Q2 revenue hit $14.6B, EPS $10.91, led by strength in M&A and financing. Assets under supervision reached $3.3T.

Prologis (PLD)
Raised development guidance to $2.75B amid a record leasing pipeline. Q2 results beat expectations with 95.1% occupancy and $5.8B in recent financings.

Alcoa (AA)
Cut 2025 shipment forecast due to tariffs and mine delays. Q2 revenue fell 10% sequentially to $3B; EBITDA declined on weaker alumina pricing.

Taiwan Semiconductor (TSM)
Q2 EPADR: $2.47 (▲ $0.14 beat), revenue: $30.07B (▼ $1.23B miss). AI demand drove 74% of wafer revenue; shares volatile in premarket.

Elevance Health (ELV)
Cut full-year EPS outlook as Medicaid and ACA cost trends rise. Revenue topped estimates at $49.4B but margin compression hit earnings.

GE Aerospace (GE)
Crushed Q2 with EPS $1.66 and $10.2B revenue. Raised FY25/FY28 guidance on surging aerospace demand and orders.

Travelers (TRV)
Q2 EPS: $6.51 (▲ $2.90 beat), driven by fewer catastrophes and solid underwriting. Revenue hit $12.1B.

MP Materials (MP)
Shares fell 6.5% after pricing a $650M offering to fund its 10X Facility. Expansion strategy seen as long-term positive despite short-term dilution.

Seven & i Holdings (SVNDY)
Stock dropped 9% after Couche-Tard withdrew a $47B buyout bid. Issues cited: valuation and regulatory concerns.

Abbott Labs (ABT)
Q2 EPS in-line at $1.26; revenue beat by $80M at $11.14B. FY organic sales outlook held at 7.5%–8%, excluding COVID testing.

Bristol-Myers Squibb (BMY) & Pfizer (PFE)
Announced 40% price cut for blood thinner Eliquis, launching September 8 to expand access via direct-to-consumer model.

Digi Power X (DGXX)
Shares soared over 30% after a deal with Super Micro (SMCI) to acquire Nvidia B200 hardware for its NeoCloud platform, set to launch Q4.

Aldeyra (ALDX)
FDA accepted resubmitted NDA for reproxalap to treat dry eye disease. PDUFA target set for December 16, 2025.

NervGen (NGEN)
Appointed Adam Rogers as interim CEO to accelerate therapeutic pipeline after Mike Kelly’s resignation.


Fundamental & Technical Watchlist


MP Materials (MP)


Price: $56.88 | Change: -2.85% | Sector: Metals & Mining
GF Score: 68

Technical Setup

  • RSI(14): 83.36 – Still in overbought territory

  • Momentum fading after recent spike

  • Support: $53.50 | Resistance: $59.20
    Day Target: $57.25 (watch for retracement toward 50-day EMA)

Fundamentals
Despite dilution from the capital raise, the Apple supply chain partnership and rare earth strategic value offer long-term upside. The 10X Facility will be key to future valuation multiples.


Abbott Laboratories (ABT)


Price: $122.75 | Change: -6.83% | Sector: Medical Devices
GF Score: 93

Technical Setup

Keep reading with a 7-day free trial

Subscribe to The Simple Side Daily to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 The Simple Side
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share